IDEAYA Biosciences, Inc.
IDYA
Classifica tra le azioni
#4744
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Prezzo delle azioni
$32.83
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$3.17B
Variazione (1 giorno)
-3.01%
Variazione (1 anno)
12.20%
Paese
US
Scambia IDEAYA Biosciences, Inc. (IDYA)
Categoria
Healthcare
EPS per IDEAYA Biosciences, Inc. (IDYA)
EPS al June 2026 TTM: $-1.92
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di IDEAYA Biosciences, Inc., l’EPS attuale della società (TTM) è $-1.92. Alla fine del 2023, la società aveva un EPS di $-1.96 un aumento rispetto a rispetto a quello del 2022, che era di $-1.42.
Storico EPS per IDEAYA Biosciences, Inc. da 2017 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-1.92 | -42.86% |
| 2024 | $-3.36 | 71.43% |
| 2023 | $-1.96 | 38.03% |
| 2022 | $-1.42 | 0.71% |
| 2021 | $-1.41 | 7.63% |
| 2020 | $-1.31 | -31.05% |
| 2019 | $-1.90 | -21.16% |
| 2018 | $-2.41 | 190.36% |
| 2017 | $-0.83 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -1,002.08% |
US
|
|
| $-7.98 | 315.63% |
US
|
|
| $-5.29 | 175.52% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,544.79% |
NL
|
